Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

Conferences

ecancer travels so that you don't have to. Explore the latest conference coverage in global oncology and find out where we are going next.

EHA 2018

14 - 17 Jun 2018

Stockholmsmässan, Stockholm, Sweden

IG rearrangement, JAK1/2 inhibition and aggressive B-cell lymphoma development...

Prof Veronika Sexl - University of Veterinary Medicine of Vienna, Vienna, Austria

IG rearrangement, JAK1/2 inhibition and aggressive B-cell lymphoma development... ( Prof Veronika Sexl - University of Veterinary Medicine of Vienna, Vienna, Austria )

CDK6 a transcriptional regulator in AML

Prof Veronika Sexl - University of Veterinary Medicine of Vienna, Vienna, Austria

CDK6 a transcriptional regulator in AML ( Prof Veronika Sexl - University of Veterinary Medicine of Vienna, Vienna, Austria )

Treating CLL with obinutuzumab

Dr Valentin Goede - St. Marien-Hospital, Cologne, Germany

Treating CLL with obinutuzumab ( Dr Valentin Goede - St. Marien-Hospital, Cologne, Germany )

Protein expression in CD138 plasma cells predicts prognosis in MM patients

Dr Irena Misiewicz-Krzeminska - Cancer Research Center, Salamanca, Spain

Protein expression in CD138 plasma cells predicts prognosis in MM patients ( Dr Irena Misiewicz-Krzeminska - Cancer Research Center, Salamanca, Spain )

Half of CLL patients who relapse on ibrutinib harbour BTK/PLCG mutations

Dr Lydia Scarfo - San Raffaele Scientific Institute, Milan, Italy

Half of CLL patients who relapse on ibrutinib harbour BTK/PLCG mutations ( Dr Lydia Scarfo - San Raffaele Scientific Institute, Milan, Italy )

First in-human trial of AMV564 for AML

Prof Peter Westervelt - Washington University School of Medicine, St Louis, USA

First in-human trial of AMV564 for AML ( Prof Peter Westervelt - Washington University School of Medicine, St Louis, USA )

SETBP1 induces transcription of developmental genes

Dr Rocco Piazza - University of Milano-Bicocca, Milan, Italy

SETBP1 induces transcription of developmental genes ( Dr Rocco Piazza - University of Milano-Bicocca, Milan, Italy )

Combination therapy for CLL in the CAPTIVATE trial

Prof Paolo Ghia - Vita-Salute San Raffaele University, Milan, Italy

Combination therapy for CLL in the CAPTIVATE trial ( Prof Paolo Ghia - Vita-Salute San Raffaele University, Milan, Italy )

Efficacy of novel agents in r/r T pro-lymphocytic leukaemia

Prof Philipp Staber - Medical University of Vienna, Vienna, Austria

Efficacy of novel agents in r/r T pro-lymphocytic leukaemia ( Prof Philipp Staber - Medical University of Vienna, Vienna, Austria )

Isatuximab in combination to treat relapsed/refractory MM

Dr Joseph Mikhael - Chief Medical Officer of the International Myeloma Foundation

$Isatuximab in combination to treat relapsed/refractory MM ( Dr Joseph Mikhael - Chief Medical Officer of the International Myeloma Foundation )$

Venetoclax in patients with previously treated WM

Prof Jorge Castillo - Dana-Farber Cancer Institute, Boston, USA

Venetoclax in patients with previously treated WM ( Prof Jorge Castillo - Dana-Farber Cancer Institute, Boston, USA )

Single cell profiling reveals key differences in architecture of stem and progenitor cells throughout life

Dr Anindita Roy - University of Oxford, Oxford, UK

Single cell profiling reveals key differences in architecture of stem and progenitor cells throughout life ( Dr Anindita Roy - University of Oxford, Oxford, UK )

ICLL07 FILO study: Minimal residual disease still detectable after first line combination therapy

Prof Pierre Feugier - University of Lorraine, Nancy, France

ICLL07 FILO study: Minimal residual disease still detectable after first line combination therapy ( Prof Pierre Feugier - University of Lorraine, Nancy, France )

Even late progressors with high risk factors in PRIMA prognostic index are more likely to die

Prof Marek Trněný - Charles University, Prague, Czech Republic

Even late progressors with high risk factors in PRIMA prognostic index are more likely to die ( Prof Marek Trněný - Charles University, Prague, Czech Republic )

Patient relevant outcomes and advocacy

Jan Geissler - CML Advocates Network, EuroBloodNET ePAG

Patient relevant outcomes and advocacy ( Jan Geissler - CML Advocates Network, EuroBloodNET ePAG )

The mutational landscape of AML

Prof Lars Bullinger - Charité University of Berlin, Berlin, Germany

The mutational landscape of AML ( Prof Lars Bullinger - Charité University of Berlin, Berlin, Germany )

Development of a risk stratifying prognostic index for ALL

Prof Anthony Moorman - Newcastle University, Newcastle, UK

Development of a risk stratifying prognostic index for ALL ( Prof Anthony Moorman - Newcastle University, Newcastle, UK )

Specification of haematopoetic stem cell fate via modulation of mitochondrial activity

Dr Mukul Girotra - Ludwig Center for Cancer Research, Lausanne, Switzerland

Specification of haematopoetic stem cell fate via modulation of mitochondrial activity ( Dr Mukul Girotra - Ludwig Center for Cancer Research, Lausanne, Switzerland )

Onset and treatment of infantile leukaemia

Dr Anindita Roy - University of Oxford, Oxford, UK

Onset and treatment of infantile leukaemia ( Dr Anindita Roy - University of Oxford, Oxford, UK )

Novel CD22 CAR-T therapy for paediatric leukaemia

Dr Jing Pan - Beijing Boren Hospital, Beijing, China

Novel CD22 CAR-T therapy for paediatric leukaemia ( Dr Jing Pan - Beijing Boren Hospital, Beijing, China )

Lymphoma guidelines in Venezuela

Dr Maria Alejandra Torres Viera - Clínica Santa Sofía, Caracas, Venezuela

Lymphoma guidelines in Venezuela ( Dr Maria Alejandra Torres Viera - Clínica Santa Sofía, Caracas, Venezuela )

Brentuximab vedotin with chemo for relapsed Hodgkin lymphoma

Dr Ramon Garcia Sanz - Hospital Universitario de Salamanca, Salamanca, Spain

Brentuximab vedotin with chemo for relapsed Hodgkin lymphoma ( Dr Ramon Garcia Sanz - Hospital Universitario de Salamanca, Salamanca, Spain )

EHA 2018: Research, collaboration and working towards cures

Prof Pieter Sonneveld - Erasmus MC, Rotterdam, Holland

EHA 2018: Research, collaboration and working towards cures ( Prof Pieter Sonneveld - Erasmus MC, Rotterdam, Holland )

Educational focus on immunotherapy at EHA

Prof John Gribben - Barts Cancer Institute, London, United Kingdom

Educational focus on immunotherapy at EHA ( Prof John Gribben - Barts Cancer Institute, London, United Kingdom )

ADC polatuzumab vedotin in combinations for relapsed lymphoma

Dr Laurie Sehn - BC Cancer Agency, Vancouver, Canada

ADC polatuzumab vedotin in combinations for relapsed lymphoma ( Dr Laurie Sehn - BC Cancer Agency, Vancouver, Canada )

iNNOVATE trial of added ibrutinib for Waldenströms Macroglobulinemia

Dr Meletios Dimopoulos - National and Kapodistrian University of Athens School of Medicine, Athens, Greece

iNNOVATE trial of added ibrutinib for Waldenströms Macroglobulinemia ( Dr Meletios Dimopoulos - National and Kapodistrian University of Athens School of Medicine, Athens, Greece )

EHA 2018: Initial results of the INSIGHT trial in multiple myeloma

Prof Efstathios Kastritis and Dr Zhengzheng Fu

EHA 2018: Initial results of the INSIGHT trial in multiple myeloma ( Prof Efstathios Kastritis and Dr Zhengzheng Fu )

A new anti-CD22 CAR T immunotherapy for paediatric leukaemia

Dr Jing Pan - Beijing Boren Hospital, Beijing, China

A new anti-CD22 CAR T immunotherapy for paediatric leukaemia ( Dr Jing Pan - Beijing Boren Hospital, Beijing, China )

EHA Topics in focus : Immunotherapy

Prof John Gribben - Barts Cancer Institute, London, United Kingdom

EHA Topics in focus : Immunotherapy ( Prof John Gribben - Barts Cancer Institute, London, United Kingdom )

Novel ADC for relapsed/refractory lymphoma

Dr Laurie Sehn - BC Cancer Agency, Vancouver, Canada

$Novel ADC for relapsed/refractory lymphoma ( Dr Laurie Sehn - BC Cancer Agency, Vancouver, Canada )$

iNNOVATE trial of added ibrutinib for Waldenströms Macroglobulinemia

Dr Meletios Dimopoulos - National and Kapodistrian University of Athens School of Medicine, Athens, Greece

iNNOVATE trial of added ibrutinib for Waldenströms Macroglobulinemia ( Dr Meletios Dimopoulos - National and Kapodistrian University of Athens School of Medicine, Athens, Greece )

EHA 2018: The unmet needs in maintenance therapy for multiple myeloma

Prof Meletios Dimopoulos, Dr Shaji Kumar, Prof Meral Beksaç and Prof Wee Joo Chng

EHA 2018: The unmet needs in maintenance therapy for multiple myeloma ( Prof Meletios Dimopoulos, Dr Shaji Kumar, Prof Meral Beksaç and Prof Wee Joo Chng )

EHA 2018: Results of the OPTIMISMM trial

Prof Paul Richardson - Dana-Farber Cancer Institute, Boston, USA

EHA 2018: Results of the OPTIMISMM trial ( Prof Paul Richardson - Dana-Farber Cancer Institute, Boston, USA )

Updated results from a phase I trial of CAR-T cell therapy for r/rMM

Dr Jesus Berdeja - Sarah Cannon Research Institute, Nashville, USA

Updated results from a phase I trial of CAR-T cell therapy for r/rMM ( Dr Jesus Berdeja - Sarah Cannon Research Institute, Nashville, USA )

Fatigue at baseline predicts shorter survival in older patients with a haematological malignancy

Prof Reinhard Stauder - University of Innsbruck, Innsbruck, Austria

Fatigue at baseline predicts shorter survival in older patients with a haematological malignancy ( Prof Reinhard Stauder - University of Innsbruck, Innsbruck, Austria )

Emerging post-transplant therapeutic options for relapsed Hodgkin lymphoma

Dr Astrid Pavlovsky - Center for Haematology, Buenos Aires, Argentina

Emerging post-transplant therapeutic options for relapsed Hodgkin lymphoma ( Dr Astrid Pavlovsky - Center for Haematology, Buenos Aires, Argentina )

Updates from Myeloma XI trial

Dr Charlotte Pawlyn - The Institute of Cancer Research, London, UK

Updates from Myeloma XI trial ( Dr Charlotte Pawlyn - The Institute of Cancer Research, London, UK )

Ribosomal lesions promote oncogenic mutagenesis

Dr Sergey Sulima - Katholieke Universiteit Leuven, Lueven, Belgium

Ribosomal lesions promote oncogenic mutagenesis ( Dr Sergey Sulima - Katholieke Universiteit Leuven, Lueven, Belgium )

Updated data from the FORTE trial of carfilzomib plus lenalidomide or cyclophosphamide for myeloma

Dr Francesca Gay - University of Torino, Torino, Italy

Updated data from the FORTE trial of carfilzomib plus lenalidomide or cyclophosphamide for myeloma ( Dr Francesca Gay - University of Torino, Torino, Italy )

Interim results of RELEVANCE trial in follicular lymphoma

Prof Franck Morschhauser - Hôpital Claude Huriez, Lille, France

Interim results of RELEVANCE trial in follicular lymphoma ( Prof Franck Morschhauser - Hôpital Claude Huriez, Lille, France )

Disease control in advanced Hodgkin lymphoma

Dr Olivier Casasnovas - CHU de Dijon, Dijon, France

Disease control in advanced Hodgkin lymphoma ( Dr Olivier Casasnovas - CHU de Dijon, Dijon, France )

Improved OS with obinutuzumab in the CLL11 study

Dr Valentin Goede - St. Marien-Hospital, Cologne, Germany

Improved OS with obinutuzumab in the CLL11 study ( Dr Valentin Goede - St. Marien-Hospital, Cologne, Germany )

Rituximab in combination therapies for FL: Interim results

Prof Franck Morschhauser - Hôpital Claude Huriez, Lille, France

Rituximab in combination therapies for FL: Interim results ( Prof Franck Morschhauser - Hôpital Claude Huriez, Lille, France )

Minimised BEACOPP exposure and toxicity for Hodgkin lymphoma gives good results

Dr Olivier Casasnovas - CHU de Dijon, Dijon, France

Minimised BEACOPP exposure and toxicity for Hodgkin lymphoma gives good results ( Dr Olivier Casasnovas - CHU de Dijon, Dijon, France )

Mapping 3D genome dynamics in B cells

Dr José Ignacio Martin-Subero - University of Barcelona, Barcelona, Spain

Mapping 3D genome dynamics in B cells ( Dr José Ignacio Martin-Subero - University of Barcelona, Barcelona, Spain )

Update on bb2121 for relapsed myeloma

Dr Jesus Berdeja - Sarah Cannon Research Institute, Nashville, USA

Update on bb2121 for relapsed myeloma ( Dr Jesus Berdeja - Sarah Cannon Research Institute, Nashville, USA )

More from ecancer